3 Reasons Hospira, Inc. Stock Could Rise

Let’s take a look at three reasons Hospira’s stock could soar to new highs.

Aug 19, 2014 at 11:55AM

Shares of Hospira (NYSE:HSP) have rallied nicely over the past 12 months, handily outperforming the broader market and closing in on all-time highs.

HSP Chart

Source: YCharts.

Last quarter, the maker of specialty injectable pharmaceuticals (SIP) and medical devices reported that its revenue rose 11% year-over-year to $1.1 billion, while its adjusted earnings per share rose 31% to $0.72 per share. 69% of Hospira's top line comes from its SIP segment, 19% comes from medication management devices, and the rest comes from other pharmaceutical products. It topped off those robust earnings by raising its top and bottom line guidance for the full year.

The key question now is whether or not Hospira's stock can keep climbing, so let's study the three most bullish cases for Hospira's continued growth. But before we get started, investors should remember that although these points highlight Hospira's greatest strengths, they do not guarantee that the stock will soar to new highs.

1. A growing footprint in biosimilars
The global market for biosimilars, or generic versions of biologic drugs, is expected to grow from $1.3 billion in 2013 to $35 billion in 2020, according to Allied Market Research. The reason is simple -- more than ten blockbuster biologic drugs with combined annual sales of $60 billion will lose patent protection in the U.S. and Europe over the next four years.

Hospira has a strong pipeline of 11 biosimilars, some shared with Celltrion and Novaquest.

Hospira's Inflectra, which is a biosimilar version of Johnson & Johnson and Merck's rheumatoid arthritis drug Remicade, was approved in Europe last year and launched in several countries in Eastern Europe. Remicade's patents are protected throughout most of Europe until February 2015 and in the U.S. until September 2018. Remicade respectively generated $6.67 billion and $2.27 billion in revenue for Johnson & Johnson and Merck in 2013.

Therefore, Hospira's portfolio of biosimilar versions of blockbuster drugs is expected to fuel stronger top line growth as additional patents expire in the U.S. over the next few years.

2. All clear in North Carolina
One of Hospira's biggest problems in the past was its plant in Rocky Mount, North Carolina, which has been scrutinized by the FDA since 2011. The company has reportedly spent $487.5 million over the past three years on product and quality charges, mostly related to upgrading the plant.

Besides being a weight on its bottom line, the plant was also bad PR for the company, which has suffered similar manufacturing issues in India and Costa Rica. The embargo of pumps made at its Costa Rica plant, issued by federal regulators last February, has further weighed on growth. 

In late July, CEO F. Michael Ball announced that the FDA finally cleared its Rocky Mount plant with no observations -- down from over 20 observations that the plant was originally slapped with. That's a highly positive development which indicates that Hospira's efforts are paying off, and hopefully provides a roadmap for Hospira to solve similar issues in India and Costa Rica.

3. A possible tax inversion
Many U.S. companies have recently lowered their corporate taxes by buying smaller companies in lower-tax nations like Ireland, then moving their headquarters overseas. Companies like Actavis, AbbVie, and Medtronic have all recently adopted that controversial strategy, known as tax inversion. A move from the U.S. to Ireland, for example, could theoretically drop a company's corporate tax rate from as high as 40% to 12.5%.

According to The Wall Street Journal, in late July, Hospira was in talks to purchase Danone's medical nutrition unit for $5 billion to move its headquarters from Illinois to France, which has a 33% corporate tax rate. If Hospira makes the move, it would not only boost its bottom line in the long run, but also diversify its portfolio away from injectables and pumps. Danone's medical nutrition unit generated €1.3 billion in revenue ($1.7 billion) last year -- which would make it a huge new division for Hospira, which reported $4 billion in revenues in 2013.

The Foolish final word
In conclusion, Hospira could certainly climb higher in the future. Its biosimilars portfolio has strong growth potential, it has taken steps to help its plants meet regulatory standards, and it could grow its bottom line and diversify its top line by acquiring Danone's medical nutrition business.

Leaked: This coming blockbuster will make even Hospira jealous
Let's face it -- the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers